In the news release, Fosun Wealth Holdings’ FinChain has reached a deep strategic cooperation with Avalanche., issued 10-Feb-2026 by Finchain Holdings (Cayman) Limited over PR Newswire, we are advised by the company that the headline, should read “Fosun Wealth Holdings’ FinChain Announces Strategic Initiative to Scale Institutional-Grade RWAs on the Avalanche Blockchain” rather than “Fosun Wealth Holdings’ FinChain has reached a deep strategic cooperation with Avalanche.” as originally issued inadvertently. The complete, corrected release follows:

Fosun Wealth Holdings’ FinChain Announces Strategic Initiative to Scale Institutional-Grade RWAs on the Avalanche Blockchain

FinChain to Integrate the Avalanche Network, Targeting the Development of RWA Tokenization for Traditional Financial Assets in Asia.

HONG KONG and NEW YORK, Feb. 10, 2026 /PRNewswire/ — FinChain, a blockchain finance platform under Fosun Wealth Holdings today announced an initiative to accelerate innovation and development of the blockchain financial ecosystem across Asia on the Avalanche blockchain. This marks the continued expansion of Avalanche across the Asian market and will enable FinChain to unlock tens of billions of dollars in traditional financial channels, supporting the on-chain deployment of standardized financial assets.

FinChain announced the official launch today of Asia’s first yield-bearing RWA stable token — FUSD (Yield-Bearing Stablecoin FUSD), which will debut on Avalanche and is planned to be integrated across the entire Avalanche DeFi ecosystem. FUSD is backed by real-world financial assets, including but not limited to Taikang Asset Management (Hong Kong) money market funds and ChinaAMC money market funds—high-liquidity, standardized financial instruments. The token supports multi-chain interoperability and provides stable yield returns. It is designed to offer institutional users—including financial institutions, crypto-native financial firms, family offices, private equity funds, and pension funds—a new crypto-financial liquidity management tool characterized by high transparency, rapid settlement, flexible liquidity, and secure, collateral-backed design.

On February 10, FinChain hosted the “2026 Asia Crypto Finance High-Level Closed-Door Forum” in Hong Kong, during which the initiative with Avalanche was formally established. This marks a major milestone in FinChain’s vision to achieve compliant interoperability across major public blockchains globally. FinChain is currently focused on building compliant cross-chain connectivity, and FUSD is positioned to become a foundational anchor asset for real, verifiable TVL across major blockchain networks.

“FUSD aims to serve as a bridge connecting Web2 standardized financial assets with the Web3 crypto-financial world,” said Zhao Chen, CEO of FinChain. “The launch of FUSD will provide public blockchains, exchanges, and asset managers with an unprecedented yield-bearing stable token. Together with Avalanche, we look forward to shaping a new on-chain landscape for trillions of dollars in financial assets.”

Avalanche, known for its high performance and compliance-friendly architecture, has become the preferred blockchain infrastructure for global financial institutions and enterprise use cases. Through its integration with FinChain, Avalanche will support the circulation and adoption of FUSD by financial institutions within its e ecosystem, highlighting its confidence in expanding real, compliant assets through globally regulated financial assets.

Jacky Kong, Head of Ava Labs Hong Kong, commented:
“Through FUSD, we will provide real financial assets in Asia with broad liquidity and collaboration opportunities within the Avalanche ecosystem and across global financial markets. This initiative with FinChain enables more traditional financial assets to seamlessly enter the blockchain world. Avalanche currently has over USD 1.2 billion in on-chain TVL and hosts high-quality RWA assets such as BlackRock BUIDL and Apollo ACRED, involving institutions including JPMorgan, Citi, and BlackRock. We expect FinChain to significantly scale the volume of real, liquid on-chain assets in the future.”

As a leading financial blockchain platform, FinChain will work closely with Avalanche to build a robust on-chain ecosystem for standardized financial assets across Asia. Leveraging FinChain’s strong network and technical capabilities, this initiative is expected to unlock tens of billions of dollars in financial channels and drive innovation in institutional asset tokenization, cross-border payments, and DeFi applications.

About Avalanche 

Avalanche is an ultra-fast, low-latency blockchain platform designed for builders who need high performance at scale. The network’s architecture allows for the creation of sovereign, efficient and fully interoperable public and private layer 1 (L1) blockchains which leverage the Avalanche Consensus Mechanism to achieve high throughput and near-instant transaction finality. The ease and speed of launching an L1, and the breadth of architectural customization choices, make Avalanche the perfect environment for a composable multi-chain future. 

Supported by a global community of developers and validators, Avalanche offers a fast, low-cost environment for building decentralized applications (dApps). With its combination of speed, flexibility, and scalability, Avalanche is the platform of choice for innovators pushing the boundaries of blockchain technology.

About FinChain

FinChain is a Web3 brand incubated by Fosun Wealth Holdings, dedicated to building a global real-world financial blockchain network. FinChain collaborates with major public blockchains worldwide to construct decentralized, compliant layers and develop a unified on-chain identity system. Its mission is to expand cross-border liquidity reserves for financial institutions and stablecoin issuers, while providing compliant decentralized infrastructure for fintech developers globally.

By fostering on-chain trust mechanisms, enhancing transparency of financial assets, and improving financing and investment efficiency, FinChain is committed to building a compliant, decentralized financial ecosystem for the future.

As headlines are dominated by AI-driven workforce restructuring, a deeper enterprise risk is emerging: organizations that fail to design human-AI collaboration into daily work are eroding productivity, speed, and competitiveness. Datatonic says the next phase of enterprise AI will be defined not by automation alone, but by governed, human-in-the-loop systems that turn AI into a workforce multiplier.

LONDON, Feb. 10, 2026 /PRNewswire/ — Public debate around artificial intelligence has been dominated by workforce reduction, but for enterprise leaders, the real threat is more subtle yet more damaging. Companies that fail to embed AI into human workflows are falling behind as productivity stalls; decision cycles stretch, and competitors move faster with hybrid human-AI operating models.

“AI isn’t just about replacing tasks. It’s about redesigning how work gets done,” said Scott Eivers, CEO of Datatonic. “The biggest risk we see in the market is productivity leakage when AI exists in isolation from the people who actually run the business.”

Boards and executive teams are entering 2026 under pressure to show returns on years of AI investment. Yet, according to Massachusetts Institute of Technology research reported in Fortune, as many as 95% of AI pilots are not pulling their weight. Many initiatives stay trapped in pilot mode, disconnected from core operations and governed poorly enough to limit trust among users. The result: AI systems generating insights that are never translated into action, leaving human teams to carry the same — or greater — operational burden as pre-AI times.

From Replacement Narratives to Real Collaboration 

Datatonic’s work with global enterprises shows that the most effective AI programs are not yet fully autonomous. Instead, they are built around human-in-the-loop (HiTL) models that combine AI’s speed with human judgment, accountability, and domain expertise.

One of the most mature examples is agent-assisted software development. Enterprises have moved beyond “vibe coding,” where AI generates code from loose prompts to spec-driven development models. In these environments, humans define, validate and even test the specification and execution plan before AI agents build modular features at scale, accelerating delivery without sacrificing control.

A similar pattern is emerging across finance, operations, and customer workflows.

• Streamlined Data Operations: GenOps workflows, where humans and AI agents collaborate to streamline data operations. The result: less manual effort, while approvals, exception handling, and escalation stay with humans.
• Finance Automation: For back-office and finance departments, AI-driven document processing is achieving up to a 70% reduction in invoice-processing costs whilst ensuring finance teams retain approval authority and anomaly resolution.

“These aren’t replacement stories,” said Andrew Harding, CTO of Datatonic. “They’re partnership stories. Humans create evaluation systems, validate plans, set guardrails, and make decisions. AI executes at speed and scale. That combination is where real enterprise value shows up.”

Trust, Governance, and the Path to Autonomy 

Despite hype around fully autonomous agents, Datatonic warns that most enterprises lack the operational maturity to deploy them safely. Critical gaps remain in agent supervision, security controls, and governance frameworks that define what AI systems can access, process, and change. Agents should operate in secure, enterprise approved shared-runtime environments which automatically mandate organisational policy whilst supporting governance and observability.

Before autonomy can scale, organizations must implement clear boundaries, approval checkpoints, and performance baselines. As models evolve, evaluation systems are essential to ensure AI continues to operate as intended, while guardrails protect against unintended actions or non-compliant outputs.

“As trust builds, companies can responsibly delegate more to AI,” Harding said. “But skipping governance doesn’t build speed — it creates risk.”

Measuring What Matters 

For enterprises under board scrutiny, success is no longer measured by novelty. Datatonic advocates for clearly documented ROI for every AI system, tied to quantifiable business outcomes, including reduced churn, faster cycle times, or measurable cost savings. Where possible, performance data should be embedded directly into agent platforms so leaders can see, in real time, whether AI is delivering on its promise.

Looking ahead 12 to 24 months, Datatonic expects enterprise work to compress from weeks to hours as agents handle preparation, analysis, and validation. Meetings will shift from status updates to decision-making. In some cases, AI agents will be used to test and invalidate ideas before teams commit resources.

“The future looks like expert departments run by smaller, nimble teams – finance, HR, marketing – each amplified by AI. It’s about higher leverage.” Eivers said. 

Future AI Action 

For enterprise and business leaders planning their next AI phase, Datatonic urges a reset: move beyond replacement narratives and invest in human-centered, governed AI systems that integrate directly into how work happens. 

“The companies that win will be those that teach people to work with AI — not around it,” Eivers said.

About Datatonic 
Datatonic is a global Data and AI consultancy and 10-time Google Cloud Partner of the Year, helping enterprises turn data and AI into clear, measurable business outcomes. As an end-to-end partner, Datatonic drives rapid transformation across strategy, architecture, deployment, enablement, and continuous optimization, empowering organizations to scale AI impact. Learn more at datatonic.com.

References:

• Gartner. Gartner Predicts Over 40% of Agentic AI Projects Will Be Canceled by End of 2027. June 25, 2025.
• Estrada, Sheryl. MIT Report: 95% of Generative AI Pilots at Companies Are Failing. Fortune, Aug. 18, 2025.
• IDC & Lenovo. CIO Playbook 2025: It’s Time for AI-nomics. 2025.
• Datatonic. GenOps at Vodafone on Google Cloud. Case study.
• Datatonic. Reducing Invoice Processing Costs with BigQuery, DocAI and GenAI. Case study.

Media Inquiries: 
Karla Jo Helms
JOTO PR
727-777-4629
jotopr.com

SHANGHAI, Feb. 10, 2026 /PRNewswire/ — As China’s new drug R&D enters the “deep waters” of homogeneous competition, the path for followers has become increasingly crowded. Target congestion, rising costs, and intensifying global races have pushed the traditional follow-on model to its limits. The industry must pivot—returning to the very starting point of innovation.

Yet a critical question remains: how can scientific discoveries cross the “Valley of Death” of industrial translation? How can a sustainable ecosystem of original innovation be continuously cultivated? The answer lies not in isolated efforts, but in cross-disciplinary co-creation.

Against this backdrop, Sanyou Bio, in partnership with Tongxieyi, jointly hosted the “2026 China New Drug Source Innovation Forum” on February 8, 2026, in Shanghai. The forum bought together visionary leaders from academia, industry, and the investment communities to explore breakthrough pathways for source innovation in new drug development and to envision the future of the biopharmaceutical industry.

The forum addressed cutting-edge fields and topics ranging from AI-driven drug discovery and personalized immunotherapies, to next-generation ADC design and human micropeptidome research; from university–industry translational collaboration to asset value re-evaluation. Under the theme “Nurturing Innovation at Its Source”, this intellectual gathering served as a platform for cross-sector collaboration, while also witnessed the official launch of the Clicklinks Innovation Hub for Original Drug Discovery, and the signing of multiple strategic partnerships.

The forum was fully livestreamed on Tongxieyi’s WeChat Channel and WeChat Mini Program with online viewership exceeding 30,000.

01 | Opening Address

Kai-Xian Chen
Research Fellow, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

China’s biopharmaceutical industry has evolved from a model dominated by generic-drug to one increasingly driven by breakthroughs in original innovation medicines. Supported by strong national policies, it has emerged as an important growth engine of global pharmaceutical innovation. Original innovative drugs now represent the core driving force of industry development and a key pillar of the Healthy China strategy.

Nevertheless, challenges remain in areas such as source innovation, core technologies, translational efficiency, and industry–academia collaboration. These challenges call for concerted efforts across the entire ecosystem. The development of original innovative medicines relies on the integration of advanced technologies, enabling platforms, high-level talent, and close collaboration among industry, academia, and research institutions.

The Shanghai Institute of Materia Medica, Chinese Academy of Sciences is committed to deepening cooperation with all stakeholders, focusing on major disease areas, and driving the industry’s transition from “following” to “running alongside” and ultimately “leading” global innovation. Through these efforts, we aim to support the globalization of China’s homegrown innovative biologics and promote the high-quality industry development.

02 Keynote Presentations

Guojun Lang
Founder & CEO, Sanyou Bio

Making Innovative Biologic Drug Development Accessible to All

Over the past decade, Sanyou Bio has remained deeply committed to the development of innovative biologics. Anchored by its intelligent Super-Trillion Antibody Library (STAL), now exceeding 11 trillion in library compacity, and proprietary AI-STAL technology, the company has built an integrated, intelligent R&D platform that seamlessly combines wet-lab and dry-lab capabilities. This platform underpins a dual-engine growth model driven by R&D innovation and commercial operations.

To date, Sanyou Bio has served over 2,000 clients worldwide and delivered over 2,000 projects. Among more than 60 collaborative programs, over 10 have successfully completed IND (Investigational New Drug) filings, and three have advanced to Phase III clinical trials.

Looking ahead, Sanyou Bio will advance its “5-5 Strategic Initiative”, leveraging the combined power of AI technologies and super-trillion-scale libraries, to establish the Clicklinks Innovation Hub for Original Drug Discovery. Through close collaboration with government, industry, academia, research institutions, and healthcare partners, Sanyou Bio aims to build a robust innovation ecosystem – advancing its mission of “Making innovative biologic drug development accessible and achievable for all”.

Hua Mao
Partner & Managing Director, Greater China
Frost & Sullivan

Global Innovative Drug Market Overview

Driven by multiple factors such as regulatory reform in drug approval and increased capital investment, China has seen a rapid surge in the number of innovative drugs under development. China has now surpassed Europe to become the world’s second-largest hub for innovative drug pipelines, trailing only the United States. At the same time, pipeline quality has improved significantly, with a rising proportion of First-in-Class (FIC) assets, particularly in advanced therapies such as cell and gene therapies (CGT) and nucleic acid-based drugs.

Although global and Chinese biotech investment and financing activity in innovative drugs has experienced fluctuations, biologics—including monoclonal antibodies, ADCs, and CGT— have remained highly favored. In China business development and licensing transaction market remain active, with companies increasingly prioritizing internationalization strategies. Overall, the industry is characterized by a biologics-driven growth model and an accelerating pace of global Expansion.

Zhimin Lv
Academician, Academia Europaea

University–Industry Collaboration to Advance Translational Research

Established in 2014, the Zhejiang University Institute of Translational Medicine is a new-generation research institute dedicated to bridging basic research and clinical medicine and accelerating the industrialization of biologic innovation. The institute operates under a co-construction, co-management, and resource-sharing model in collaboration with seven affiliated hospitals of Zhejiang University School of Medicine, and is supported by a high-caliber multidisciplinary talent team.

The institute has achieved significant outcomes in scientific research projects, academic publications, translational achievements, and clinical studies. Through close collaboration with industry partners, it conducts diversified drug R&D programs spanning antibodies, peptides, and small molecules, targeting a wide range of diseases including oncology, metabolic liver diseases, autoimmune disorders, and neurodegenerative diseases. These efforts collectively promote the advancement of pharmaceutical R&D and the sustainable development of the biologic industry.

Bin Li
Research Fellow, Shanghai Institute of Immunology

Current Status and Future Perspectives of Personalized Immunotherapy

Personalized immunotherapy has emerged as a major frontier in oncology. Its therapeutic efficacy is largely determined by the immune characteristics of the tumor microenvironment. Advances in AI and spatiotemporal multi-omics are now providing critical support for improving precision and personalization in immunotherapy.

Our research team has long been dedicated to the study of FOXP3+ Treg research and has proposed the Immunological Oscillation Theory. By integrating a multi-omics analytical framework established through tripartite collaboration, we aim to facilitate the translation of Treg-based therapies from fundamental research to clinical application, ultimately contributing to the advent of single-cell–level precision medicine.

Tianyi Qiu
Young Principal Investigator, Fudan University

Accelerating Large-Molecule Drug Discovery and Design with Artificial Intelligence

Mutation escape remains a key factor affecting efficacy of antibodies and vaccines. To address three core challenges—immunogenicity prediction, antigen similarity assessment, and high-throughput design and screening—our team has developed the SEPPA series of epitope prediction algorithms and the CE-BLAST antigen similarity prediction algorithm, achieving superior accuracy than conventional tools.

We have also established a high-throughput computational workflows, applying it to antibody and vaccine design case studies for SARS-CoV-2, norovirus, and influenza. Experimental validation has confirmed the effectiveness of these designs, resulting in a comprehensive technology pipeline that spans from pathogen analysis to antibody/vaccine discovery and optimization.

Hailiang Zheng
Vice President, R&D, Sanyou Bio

Application of AI-STAL in Source Innovation for New Drug Discovery

The global antibody drug market is expanding rapidly, and generative AI is increasingly empowering R&D. Traditional antibody discovery, however, faces challenges such as long development cycles. The AI-STAL establishes a comprehensive technology pathway from de novo design to in vitro and in vivo validation, centered on an integrated wet-lab and dry-lab workflow. It is supported by a super-trillion antibody library and an intelligent R&D platform, providing a robust foundation for high-efficiency discovery. Looking ahead, this technology is expected to transform biologics R&D toward precise, on-demand design, accelerating innovation at the very source of new drug development.

Xin Xie
Deputy Director, National Center for Drug Screening

New Drug Discovery Targeting G Protein-Coupled Receptors (GPCRs)

G protein-coupled receptors (GPCRs) represent the largest family of membrane protein receptors in the human body, playing key roles numerous physiological processes. Dysregulation of GPCR function is closely associated with a wide range of diseases, making GPCRs a central target family in drug discovery. Currently, approximately 30–40% of approved drugs globally target GPCRs, covering therapeutic areas such as neurology, endocrinology, immunology and metabolism.

In 2025, sales of GPCR-targeted anti-obesity drugs semaglutide and tirzepatide are each achieved to exceed USD 35 billion, highlighting the substantial value of GPCRs in new drug discovery.

The speaker provides an overview of GPCR structure and signal transduction characteristics, as well as new drug screening methodologies. As a case study, GPR84, a GPCR with key role in immune and inflammatory disease, is discussed. This includes research on its functions in colitis, lung injury, and atopic dermatitis, the discovery and optimization of novel structural ligands, and ongoing new drug development efforts targeting colitis and atopic dermatitis.

Guoqing Cao
Chairman, Minghui Pharma

Next-Generation ADC Molecule Design

The development of innovative drugs is inherently long and high-risk, relying on scientific innovation, technological support, outstanding teams, and perseverance. ADC represents a major breakthrough in cancer therapy, now expanding from hematologic malignancies to solid tumors. Their rapid development is driven by multidimensional technological upgrades, including targets, targeting agents, linkers, and payloads.

Minghui’s SuperTopoi ADC platform demonstrates significant advantages, featuring highly efficient proprietary payloads, clinically validated linkers, and optimized antibody engineering, achieving strong safety profiles and antitumor efficacy. Among its lead candidates, MHB088C has shown remarkable efficacy and excellent safety and tolerability across multiple tumor clinical studies, with a favorable benefit-risk profile, and its clinical development is progressing steadily.

Yujie Xia
Product Director, Sanyou Bio

Launch of Clicklinks Original Innovative Drug Innovation Hub

The Clicklinks Original Innovative Drug Innovation Hub is founded on the principles of openness and efficiency, industry collaboration, mutual benefit and win-win outcomes, and value realization.

It is committed to building a sustainable platform that integrates upstream and downstream partners and accelerates the translation of research outcomes.

Powered by AI-STAL, the Clicklinks focuses on nine major disease areas and over ten types of innovative molecular modalities, ensuring precise alignment with unmet clinical needs.

Its development aims to foster global ecosystem collaboration and establish deeply integrated strategic partnerships, supporting partners in the continuous development of original innovative drugs. Our vision is to cultivate a thriving “Innovation Rainforest”, where an open ecosystem empowers partners across all dimensions of drug discovery and development.

03 Signing Ceremony

The vitality of source innovation lies not only in breakthroughs in cutting-edge science, but also in the smooth translation from laboratory research to industry and the co-building of an innovation ecosystem.

At this forum, the “AI-STAL–Driven Clicklinks Original Innovative Drug Innovation Hub Signing Ceremony” was officially held with great prominence. Fourteen distinguished representatives from academia and industry jointly took the stage to witness this milestone. They are:

Hongchen Gu: President, Hefei Early Screening Institute, Shanghai Jiao Tong University
Naping Tang: Vice President, InnoStar
Weiqin Ni: Deputy General Manager, Liferiver
Kai Tan: General Manager, Dragon Sail Pharmaceutical
Shumin Wang: General Manager, TransReco
Henghao Xu: General Manager, Yugong Bio
Linglong Zou: General Manager, Kanwhish Biotech
Feng Tan: General Manager, NovoPro
Guozhen Xing: General Manager, AnLing Biomed
Zhenghai Li: General Manager, NephroMedicine
Dongxiao Feng: Deputy General Manager, Shanghai Model Organisms Center (SMOC)
Donglin Sun: Deputy General Manager, Acemab
Yichun Luo: Medical Director, Revvity
Guojun Lang: Founder & CEO, Sanyou Bio

04 Roundtable Dialogues

Entrepreneurs and Scientists in discussion on the Ecosystem of Original Innovative Drug R&D
Zhenze Hu (Moderator): Founder, ZhenSighti
Dongzhou Liu: Chief Strategy Officer (CSO), Huadong Medicine
Qi He: Co-Founder & CEO, TandemAI
Yiwei Chu: Professor, Fudan University, Vice President, Chinese Society of Immunology (CSI)
Xuanhui Xie: Managing Partner, TVM Capital / ValueSeek Ventures
Yongqi Chen: Founder & CEO, Resproly
Sunxing Qin: Chairman, LePure Biotech

China’s ecosystem for innovative drugs has taken shape and already demonstrates significant achievements. Strengths are particularly notable in CRO/CDMO services and early-stage R&D, with active outbound licensing and collaboration. However, several key gaps remain. Payment and reimbursement systems are underdeveloped, translational pathways from basic research to Proof of Concept (POC) are incomplete, and there is a shortage of talent, insufficient global commercialization capabilities, and limited collaboration across the industry chain.

In terms of early-stage innovation risk, the translation of academic research remains challenging, necessitating coordinated efforts among enterprises, investors, and government. Large pharmaceutical companies are increasingly willing to engage in breakthrough early-stage projects. On the non-technical side, low tolerance for failure, decision-making inefficiencies, and misallocation of resources have created competitive “overwork” pressure, which hinder ecosystem efficiency.

Over the next 5–10 years, the ecosystem is expected to enter a phase of optimization, integration, and deeper globalization. Recognition of clinical data will increase, differentiated innovation will become mainstream. China is poised to produce globally leading pharmaceutical companies, achieving a leap from high competition to high-quality innovation.

Source Innovation and the Re-Evaluation of China’s Innovative Drug Assets
Zengjiang Cheng (Moderator): Vice Chairman, China Pharmaceutical Industry Promotion Association Founder & Chairman, Tongxieyi
Tao Ru: Managing Director, Shanghai Guotou Pioneer Private Equity Fund
Jian’er Yao: Chairman, Tellgen Corporation
Yu Zhou: Partner, Huatai Zijin Fund
Jia Li: Partner, Longshine Investment
Jie Chen: Expert, Technology Finance DepartmentBank of Communications
Suyang Wang: General Manager, Technology Finance Division Shanghai Rural Commercial Bank

China’s innovative drug assets have transitioned from imitation to differentiated, engineering-driven innovation, attracting growing international attention. BD transaction upfront payments have grown counter-cyclically. Nevertheless, challenges remain, including homogeneous competition, valuation dependence on oversea markets, and tighter Hong Kong IPO policies, making high-quality differentiated assets the core of the market.

On the international front, supply is increasing, but clinical value and differentiation remain critical. Overseas companies often acquire Chinese assets for efficiency reasons, highlighting the need to enhance global commercialization capabilities in the long term. From a capital perspective, investment institutions urge the market to avoid following trends, remain patient, and focus on first-in-class innovation. Banks are supporting innovative drugs across the full chain through credit loans, equity-linked products, and clinical loans, emphasizing early evaluation of team and data, and in some cases reducing personal joint liability. These measures provide both timely support and strategic capital reinforcement, making financial backing more effective and targeted.

In terms of source innovation, universities and research institutes focus on fundamental target discovery, while enterprises lead engineering-based translation and implementation. Effective industry–academia–research collaboration, along with tolerance for innovation risk, is essential to foster a healthy and sustainable ecosystem.

05 Closing Remarks

Zengjiang Cheng
Vice Chairman, China Pharmaceutical Industry Promotion Association
Founder & Chairman, Tongxieyi

The forum featured nine keynote presentations and two roundtable discussions, bringing together leading experts from China’s top scientific institutions and universities. In-depth exchanges focused on global new drug R&D, AI-driven drug discovery, next-generation ADC technologies, and personalized medicine, highlighting China’s positive trajectory from “following” to “running alongside” and even “leading” in these cutting-edge fields. Notably, significant internationally competitive achievements and teams have emerged in key areas such as AI-driven drug development and precision medicine.

During the forum, Sanyou Bio signed strategic agreements with multiple partners to officially launch the Clicklinks Innovative Drug Innovation Hub, marking a major step forward in industry–academia–research collaboration. We look forward to Sanyou Bio achieving new milestones over the next decade, supporting the next wave of innovation in China’s biopharmaceutical innovation.

Wishing everyone success and momentum in the Year of the Horse.

About Sanyou

Sanyou Biopharmaceuticals is a high-tech biopharmaceutical enterprise driven by its super-trillion molecule library and artificial intelligence technology, with the mission of “making innovative biologics R&D easy for clients worldwide”.

Sanyou Bio has been dedicated to developing a world-class innovative biological drug R&D hub. The company is centered on its AI-driven super-trillion antibody library (AI-STAL) and supported by its world-leading, integrated and intelligent R&D platform for innovative biologics development that seamlessly combines in silico and wet-lab capabilities. Sanyou drives the global development and industrialization of innovative new drugs through diversified business models.

Headquartered in Shanghai, China, Sanyou has established global business centers across Asia, North America, and Europe, forming an international business network. The company currently operates and has planned over 20,000 square meters of R&D and GMP facilities.

Sanyou has established strong collaborations with more than 2,000 pharmaceutical and biotech companies worldwide, empowering over 1,200 new drug discovery and development projects. It has completed more than 50 collaboration projects, over 10 of which have advanced to IND approval and clinical development stages.

The company has filed over 130 invention patents, with more than 30 granted. It has also obtained over 10 national and international qualifications and system certifications, including National High-Tech Enterprise, Shanghai “Specialized and Innovative” Enterprise, ISO9001, and ISO27001.

CAMBRIDGE, Mass., Feb. 10, 2026 /PRNewswire/ — Insilico Medicine (“Insilico”, 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), China Medical System Holdings Limited (“CMS”, 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, today announced a series of AI‑empowered drug discovery collaborations across multiple projects in the fields of central nervous system and autoimmune diseases.

According to the collaboration agreement, the two parties will combine Insilico Medicine’s validated AI platform and AI-enabled innovative drug discovery and development capabilities with CMS’s experienced R&D team and deep disease-area expertise to jointly advance the co-development of no fewer than two R&D programs. Insilico Medicine is also expected to receive R&D funding support of up to several tens of millions of HKD for each program. This collaboration will fully leverage the complementary strengths of both parties across the entire value chain of drug discovery, clinical development, and commercialization. By integrating resources and technologies, the companies aim to accelerate the research, development, and translation of high-potential innovative therapies. Insilico will capitalize on its Pharma. AI platform and its technological capabilities in target discovery, small-molecule design, and optimization to enable efficient screening and validation of candidate molecules. CMS will contribute its extensive experience and well-established networks in clinical development strategy, regulatory pathway planning, clinical trial execution, and commercial promotion, to advance projects from preclinical stages into clinical development and ultimately to commercialization.

Under this collaboration framework, the parties will jointly optimize project decision-making, shorten development timelines, and improve clinical success rates, thereby significantly accelerating the entire journey from laboratory discovery to patient access. This strong partnership is expected not only to bring innovative medicines into clinical development and to market more rapidly, but also to offer patients more innovative and accessible treatment options, ultimately improving health outcomes and quality of life.

Mr. LAM Kong, the Chairman, Chief Executive Officer, President and Executive Director of CMS said: “CMS has always been committed to addressing clinical needs through a dual-drive model of ‘collaborative development and independent R&D.’ We continue to enrich our pipeline with global first-in-class (FIC) and best-in-class (BIC) innovative assets, efficiently advancing their clinical research, development, and commercialization to empower the continuous translation of scientific achievements into clinical practice. Insilico Medicine’s leadership in AI drug discovery platforms and data-driven R&D is strategically complementary to CMS’s capabilities in innovative R&D and clinical translation. In addition, CMS has built solid strengths in clinical development systems, regulatory submission expertise, and a broad commercialization network. We look forward to further deepening our collaboration on the existing foundation to accelerate the delivery of more clinically meaningful innovations to patients with greater speed and quality, improving the accessibility and affordability of medicines and better meeting the growing clinical needs.”

“We are delighted to collaborate with China Medical System,” said Feng Ren, PhD, Co-CEO and Chief Scientific Officer of Insilico Medicine. “This strategic collaboration with CMS is a key step for Insilico Medicine in advancing our mission of ‘AI‑empowered, full‑lifecycle innovative drug R&D’. Under this collaboration framework, we look forward to leveraging resource sharing and joint decision‑making to significantly shorten the development cycle of high‑potential innovative drugs, enhance translational efficiency and clinical success rates, and accelerate the journey of more innovative molecules from ‘proof of concept’ to truly ‘benefiting patients’. Going forward, the two parties will continue to deepen multi‑dimensional collaboration in pipeline layout, clinical strategy, and global partnerships, further improving the accessibility of innovative medicines, providing patients with more differentiated treatment options.”

Harnessing state-of-the-art AI and automation technologies, Insilico has significantly improved the efficiency of preclinical drug development, setting a benchmark for AI-driven drug R&D. While traditional early-stage drug discovery typically requires an average of 4.5 years, Insilico has nominated 20 preclinical candidates from 2021 to 2024, with an average timeline—from project initiation to preclinical candidate (PCC) nomination—of just 12 to 18 months per program, with only 60 to 200 molecules synthesized and tested in each program.

About CMS

CMS (HKEX stock code:867; SGX stock code: 8A8) is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses, bringing economies of scale in specialty fields.

About Insilico Medicine

Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend health longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.

By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com